Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
In development
Reference number: GID-TA10745
Expected publication date:
As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-June 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.